Last reviewed 2026-05-14 · How we verify

Beta-D-Glucuronamide (GLUCURONAMIDE)

Phase 2 active Small molecule

Beta-D-Glucuronamide (generic name: GLUCURONAMIDE) is a glucuronamide drug. It is currently in Phase 2 development.

Beta-D-Glucuronamide works by interacting with cellular processes, although the exact mechanism is unknown.

Beta-D-Glucuronamide, also known as GLUCURONAMIDE, is a small molecule drug in the glucuronamide class. Its exact mechanism of action and target are unknown, but it is believed to work by interacting with cellular processes. GLUCURONAMIDE's commercial status and approved indications are currently unclear. Further research is needed to determine its efficacy and safety profile. As a result, it is not yet a widely recognized or used medication.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	GLUCURONAMIDE
Drug class	glucuronamide
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your cells are like a factory, and Beta-D-Glucuronamide is a tool that helps the factory run more efficiently. However, we don't know exactly how it fits into the factory's machinery or what it does to help it work better. More research is needed to understand its effects on the body.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Beta-D-Glucuronamide CI brief — competitive landscape report
Beta-D-Glucuronamide updates RSS · CI watch RSS

Frequently asked questions about Beta-D-Glucuronamide

What is Beta-D-Glucuronamide?

Beta-D-Glucuronamide (GLUCURONAMIDE) is a glucuronamide drug.

How does Beta-D-Glucuronamide work?

Beta-D-Glucuronamide works by interacting with cellular processes, although the exact mechanism is unknown.

What is the generic name of Beta-D-Glucuronamide?

GLUCURONAMIDE is the generic (nonproprietary) name of Beta-D-Glucuronamide.

What drug class is Beta-D-Glucuronamide in?

Beta-D-Glucuronamide belongs to the glucuronamide class. See all glucuronamide drugs at /class/glucuronamide.

What development phase is Beta-D-Glucuronamide in?

Beta-D-Glucuronamide is in Phase 2.

Drug class: All glucuronamide drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing